{"id":"contrave","rwe":[],"tags":[],"safety":{"boxedWarnings":["WARNING: SUICIDAL THOUGHTS AND BEHAVIORS WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for major depressive disorder and other psychiatric disorders. ( 5.1 ) Monitor for worsening and emergence of suicidal thoughts and behaviors. ( 5.1 ) CONTRAVE is not approved for use in pediatric patients. ( 5.1 ) SUICIDALITY AND ANTIDEPRESSA"],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Nausea","drugRate":"6.3%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"1.7%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"1.1%","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Myocardial infarction","drugRate":"","severity":"serious"},{"effect":"Tachycardia","drugRate":"","severity":"serious"},{"effect":"Cholecystitis","drugRate":"","severity":"serious"},{"effect":"Pneumonia","drugRate":"","severity":"serious"},{"effect":"Kidney infection","drugRate":"","severity":"serious"},{"effect":"Staphylococcal infection","drugRate":"","severity":"serious"},{"effect":"Presyncope","drugRate":"","severity":"serious"},{"effect":"Hematochezia","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["Naltrexone/Bupropion","pharmaceutical","Naltrexone/Bupropion-NB"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"485ff360-32c8-11df-928b-0002a5d5c51b","title":"CONTRAVE EXTENDED-RELEASE (NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE) TABLET, EXTENDED RELEASE [NALPROPION PHARMACEUTICALS LLC]"},"ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-28T00:31:08.952Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[],"indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04599478","phase":"PHASE2, PHASE3","title":"Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2021-06-29","conditions":"Loss-of-control Eating, Obesity/Overweight","enrollment":160},{"nctId":"NCT07213466","phase":"PHASE4","title":"Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-01-19","conditions":"Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder","enrollment":100},{"nctId":"NCT04605081","phase":"PHASE2, PHASE3","title":"Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2022-01-10","conditions":"Loss-of-Control Eating, Obesity/Overweight","enrollment":100},{"nctId":"NCT05579249","phase":"PHASE4","title":"A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-01-19","conditions":"Obesity","enrollment":500},{"nctId":"NCT03946111","phase":"PHASE2, PHASE3","title":"Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders","status":"COMPLETED","sponsor":"Yale University","startDate":"2019-08-07","conditions":"Binge-Eating Disorder, Obesity","enrollment":3},{"nctId":"NCT06482411","phase":"","title":"Risk Factors Affect Weight Loss Outcomes After Treatment.","status":"COMPLETED","sponsor":"E-DA Hospital","startDate":"2024-06-27","conditions":"Weight Regain","enrollment":3602},{"nctId":"NCT06098079","phase":"PHASE4","title":"Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)","status":"RECRUITING","sponsor":"Currax Pharmaceuticals","startDate":"2024-01-03","conditions":"Obesity","enrollment":8600},{"nctId":"NCT06854614","phase":"PHASE4","title":"Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2025-03-01","conditions":"Obesity","enrollment":150},{"nctId":"NCT05756764","phase":"","title":"Anti-obesity Pharmacotherapy and Inflammation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2023-06-01","conditions":"Obesity","enrollment":30},{"nctId":"NCT06809166","phase":"PHASE4","title":"Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity","status":"RECRUITING","sponsor":"The Royal's Institute of Mental Health Research","startDate":"2024-07-04","conditions":"Obesity, Weight Loss, Weight Management","enrollment":40},{"nctId":"NCT06090461","phase":"","title":"Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)","status":"COMPLETED","sponsor":"Currax Pharmaceuticals","startDate":"2014-09","conditions":"Obesity","enrollment":31889},{"nctId":"NCT05157698","phase":"PHASE2, PHASE3","title":"Pharmacological and Behavioral Treatment After Bariatric Surgery","status":"RECRUITING","sponsor":"Yale University","startDate":"2022-01-13","conditions":"Obesity","enrollment":160},{"nctId":"NCT05919797","phase":"PHASE4","title":"Weight Loss Study: Genetics and Response to Naltrexone/Bupropion","status":"RECRUITING","sponsor":"Columbia University","startDate":"2023-06-08","conditions":"Obesity","enrollment":120},{"nctId":"NCT04499950","phase":"PHASE2","title":"Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-02-08","conditions":"Breast Cancer, Overweight or Obesity","enrollment":53},{"nctId":"NCT05812183","phase":"PHASE4","title":"Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2023-07-09","conditions":"Dyspnea, Quality of Life","enrollment":""},{"nctId":"NCT03431831","phase":"PHASE4","title":"Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-07-01","conditions":"Obesity","enrollment":86},{"nctId":"NCT03539900","phase":"PHASE2, PHASE3","title":"Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder","status":"COMPLETED","sponsor":"Yale University","startDate":"2018-04-17","conditions":"Binge-Eating Disorder","enrollment":89},{"nctId":"NCT03047005","phase":"PHASE2, PHASE3","title":"Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-08-28","conditions":"Binge-Eating Disorder, Obesity","enrollment":68},{"nctId":"NCT03063606","phase":"PHASE2, PHASE3","title":"Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-09-05","conditions":"Binge-Eating Disorder, Obesity","enrollment":31},{"nctId":"NCT06089824","phase":"","title":"Drug Utilisation of Mysimba/Contrave","status":"COMPLETED","sponsor":"Currax Pharmaceuticals","startDate":"2014-09","conditions":"Obesity","enrollment":43324},{"nctId":"NCT04553263","phase":"EARLY_PHASE1","title":"Relapse Prevention in Stimulant Use Disorder","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2023-06-11","conditions":"Stimulant Use, Relapse, Cognitive Function","enrollment":""},{"nctId":"NCT04589130","phase":"PHASE4","title":"Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program.","status":"UNKNOWN","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2021-02-01","conditions":"Obesity","enrollment":89},{"nctId":"NCT04587843","phase":"PHASE4","title":"A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgery","status":"UNKNOWN","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2021-04-01","conditions":"Obesity","enrollment":18},{"nctId":"NCT03374956","phase":"PHASE3","title":"Individualized Obesity Pharmacotherapy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-12-11","conditions":"Obesity","enrollment":193},{"nctId":"NCT04902625","phase":"PHASE4","title":"Use of Mysimba in Patients With Weight Regain After Bariatric Surgery","status":"UNKNOWN","sponsor":"Zuyderland Medisch Centrum","startDate":"2023-03-21","conditions":"Obesity, Morbid, Bariatric Surgery Candidate, Medication Persistence","enrollment":116},{"nctId":"NCT03045341","phase":"PHASE2, PHASE3","title":"Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-02-27","conditions":"Binge-eating Disorder, Obesity","enrollment":136},{"nctId":"NCT03799198","phase":"PHASE4","title":"Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-01-07","conditions":"Obesity","enrollment":200},{"nctId":"NCT02736474","phase":"PHASE4","title":"Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2016-05","conditions":"Obese, Cigarette-smoking, Schizophrenia","enrollment":22},{"nctId":"NCT02317744","phase":"NA","title":"Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-12","conditions":"Binge Eating Disorder","enrollment":22},{"nctId":"NCT01601704","phase":"PHASE3","title":"Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)","status":"TERMINATED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2012-06","conditions":"Obesity, Overweight","enrollment":8910},{"nctId":"NCT02638129","phase":"PHASE4","title":"Naltrexone/Bupropion Cardiovascular Outcomes Study","status":"TERMINATED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2016-01","conditions":"Obesity, Cardiovascular Diseases","enrollment":67},{"nctId":"NCT01359930","phase":"PHASE1","title":"Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2011-08","conditions":"Methamphetamine Dependence","enrollment":16},{"nctId":"NCT02735603","phase":"PHASE1","title":"Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2016-04","conditions":"Heart Repolarization","enrollment":84},{"nctId":"NCT02745912","phase":"PHASE1","title":"Study to Evaluate the Effect of Naltrexone and Bupropion Combination on the Pharmacokinetics of Metformin in Healthy Participants","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2016-04","conditions":"Healthy Subjects","enrollment":30},{"nctId":"NCT02259179","phase":"PHASE1","title":"Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2014-09","conditions":"Healthy","enrollment":80},{"nctId":"NCT00563563","phase":"PHASE2","title":"A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2007-10","conditions":"Nicotine Dependence, Overweight, Obesity","enrollment":30},{"nctId":"NCT00364871","phase":"PHASE2","title":"Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity","status":"COMPLETED","sponsor":"Orexigen Therapeutics, Inc","startDate":"2005-04","conditions":"Obesity","enrollment":410}],"_emaApprovals":[],"_faersSignals":[{"count":1977,"reaction":"NAUSEA"},{"count":1109,"reaction":"HEADACHE"},{"count":1042,"reaction":"DIZZINESS"},{"count":671,"reaction":"VOMITING"},{"count":643,"reaction":"CONSTIPATION"},{"count":582,"reaction":"FEELING ABNORMAL"},{"count":517,"reaction":"FATIGUE"},{"count":404,"reaction":"ANXIETY"},{"count":392,"reaction":"INSOMNIA"},{"count":375,"reaction":"DIARRHOEA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[{"date":"20210414","type":"SUPPL","sponsor":"NALPROPION","applicationNumber":"NDA200063"},{"date":"20170310","type":"SUPPL","sponsor":"NALPROPION","applicationNumber":"NDA200063"},{"date":"20150608","type":"SUPPL","sponsor":"NALPROPION","applicationNumber":"NDA200063"},{"date":"20200804","type":"SUPPL","sponsor":"NALPROPION","applicationNumber":"NDA200063"},{"date":"20231130","type":"SUPPL","sponsor":"NALPROPION","applicationNumber":"NDA200063"},{"date":"20180613","type":"SUPPL","sponsor":"NALPROPION","applicationNumber":"NDA200063"},{"date":"20170504","type":"SUPPL","sponsor":"NALPROPION","applicationNumber":"NDA200063"},{"date":"20170127","type":"SUPPL","sponsor":"NALPROPION","applicationNumber":"NDA200063"},{"date":"20170106","type":"SUPPL","sponsor":"NALPROPION","applicationNumber":"NDA200063"},{"date":"20150316","type":"SUPPL","sponsor":"NALPROPION","applicationNumber":"NDA200063"},{"date":"20140910","type":"ORIG","sponsor":"NALPROPION","applicationNumber":"NDA200063"},{"date":"20251105","type":"SUPPL","sponsor":"NALPROPION","applicationNumber":"NDA200063"},{"date":"20251105","type":"SUPPL","sponsor":"NALPROPION","applicationNumber":"NDA200063"},{"date":"20240507","type":"SUPPL","sponsor":"NALPROPION","applicationNumber":"NDA200063"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":59,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Contrave","genericName":"Contrave","companyName":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","companyId":"sidney-kimmel-comprehensive-cancer-center-at-johns-hopkins","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":6,"withResults":2},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}